HEMATOLOGIC RECOVERY INDUCED BY ELTROMBOPAG IN PATIENT WITH APLASTIC ANEMIA AFTER TEMOZOLOMIDE

HEMATOLOGIC RECOVERY INDUCED BY ELTROMBOPAG IN PATIENT WITH APLASTIC ANEMIA AFTER TEMOZOLOMIDE

Objective: Presenting a rare clinical case of a patient with Aplastic Anemia (AA) developed after treatment with Temozolomide who achieved complete hematologic recovery induced by eltrombopag. Methods: Retrospective descriptive study of a clinical case carried out through data collection from HSPE m...

Full description

Bibliographic Details
Main Authors:	ACP Silva, JOR Cassiano, NN Kloster, CM Freitas, MM Garcia, RDA Conserva, CEF Gonçalves, VLP Figueiredo
Format:	Article
Language:	English
Published:	Elsevier 2023-10-01
Series:	Hematology, Transfusion and Cell Therapy
Online Access:	http://www.sciencedirect.com/science/article/pii/S2531137923002730

Similar Items

MULTIPLE MYELOMA AND MYELOMATOUS ASCITES: A CASE REPORT
by: CM Freitas, et al.
Published: (2023-10-01)

LINFO-HISTIOCITOSE HEMOFAGOCÍTICA EM PACIENTE HIV+ COM LINFOMA DE HODGKIN
by: NN Kloster, et al.
Published: (2023-10-01)

IMMUNOLOGICAL RESPONSE ASSOCIATED WITH DERMATOLOGICAL LESIONS IN A PATIENT WITH MYELODYSPLASTIC NEOPLASIA
by: JOR Cassiano, et al.
Published: (2023-10-01)

SURGERY FOR PRIMARY DIFFUSE LARGE B-CELL-LYMPHOMA OF THE CENTRAL NERVOUS SYSTEM - A CASE REPORT
by: JOR Cassiano, et al.
Published: (2023-10-01)

MYELOID ACUTE LEUKEMIA WITH INCREASED BASOPHILIC CELLS AND HISTAMINE RELEASE EPISODES
by: JOR Cassiano, et al.
Published: (2023-10-01)

Role of eltrombopag in severe aplastic anemia treatment in children
by: Min-Yu Su, et al.
Published: (2021-11-01)

MYELODYSPLASIA/MYELOPROLIFERATIVE WITH RING SIDEROBLAST AND THROMBOCYTOSIS OR UNCLASSIFIABLE (MDS/MPNI)
by: MM Garcia, et al.
Published: (2023-10-01)

Efficacy of eltrombopag with immunosuppressive therapy for children with acquired aplastic anemia
by: Yufei Zhao, et al.
Published: (2023-01-01)

Evaluation of eltrombopag in patients with aplastic anemia in real-world experience
by: Akiko Konishi, et al.
Published: (2019-01-01)

Current evidence and the emerging role of eltrombopag in severe aplastic anemia
by: Beatrice Drexler, et al.
Published: (2021-03-01)

MYELODYSPLASTIC SYNDROME RESPONDING TO THE AZACITIDINE PROTOCOL ASSOCIATED WITH HIGH DOSES OF VITAMINS
by: VM Sthel, et al.
Published: (2023-10-01)

CASE REPORT: ACUTE MYELOID LEUKEMIA MANIFESTING FEATURES OF VEXAS SYNDROME IN ELDERLY WOMAN
by: CM Freitas, et al.
Published: (2023-10-01)

WARM AUTOIMMUNE HEMOLYTIC ANEMIA ASSOCIATED WITH EPSTEIN BARR VIRUS INFECTION
by: JPV Junior, et al.
Published: (2023-10-01)

LEUKAPHERESIS AS A TEMPORIZING MEASURE IN LEUKOSTASIS DUE TO ACUTE MYELOID LEUKEMIA
by: ACP Silva, et al.
Published: (2023-10-01)

Efficacy and safety of eltrombopag in Chinese patients with refractory or relapsed severe aplastic anemia
by: Hong Chang, et al.
Published: (2023-11-01)

Adding cyclosporin A to eltrombopag for aplastic anemia secondary to chemotherapy for solid cancers
by: Ziqi Wan, et al.
Published: (2023-05-01)

LEUCEMIA LINFOCÍTICA CRÔNICA ASSOCIADA A ANEMIA HEMOLÍTICA AUTOIMUNE COM RESPOSTA SOMENTE APÓS INTRODUÇÃO DE IBRUTINIBE
by: ASH Gallotti, et al.
Published: (2023-10-01)

RAPID REDUCTION OF LYMPH NODE ENLARGEMENT IN A PATIENT WITH CHRONIC LYMPHOCYTIC LEUKEMIA TREATED WITH IBRUTINIB
by: JOR Cassiano, et al.
Published: (2023-10-01)

Development of Aplastic Anemia during Treatment of Anaplastic Astrocytoma with Temozolomide
by: Karam Khaddour, et al.
Published: (2020-10-01)

NATIONAL EXPERIENCE WITH IMMUNOSUPPRESSIVE THERAPY AND ELTROMBOPAG IN CHILDREN WITH APLASTIC ANEMIA- REAL WORLD DATA
by: Katarzyna Pawelec, et al.
Published: (2023-12-01)

The efficacy and the safety of eltrombopag in pediatric patients with severe aplastic anemia: a systematic review
by: Maria Maddalena Marrapodi, et al.
Published: (2023-04-01)

The Impact of Eltrombopag Administration on the Clinical Course of Severe Refractory Fatal Acquired Aplastic Anemia
by: Ayşe Işık, et al.
Published: (2013-09-01)

Eltrombopag inhibits TET dioxygenase to contribute to hematopoietic stem cell expansion in aplastic anemia
by: Yihong Guan, et al.
Published: (2022-02-01)

Budget Impact Of Eltrombopag As First-Line Treatment For Severe Aplastic Anemia In The United States
by: Tremblay G, et al.
Published: (2019-11-01)

Aplastic anemia in adult and pediatric hematology
by: Charlotte Niemeyer, (Coordinating Author)
Published: (2019-06-01)

Cyclosporin A and eltrombopag for aplastic anemia: A promising and cost effective approach: A tertiary care pediatric hematology-oncology centre experience
by: Ritika Khurana, et al.
Published: (2022-01-01)

Response of Eltrombopag in immune thrombocytopenia and acquired idiopathic aplastic anemia: A single-center experience
by: Abdul Muqtadir Abbasi, et al.
Published: (2022-01-01)

Eltrombopag treatment of a dog with idiopathic aplastic pancytopenia
by: Darren Kelly, et al.
Published: (2020-03-01)

Predicting Response of Severe Aplastic Anemia to Rabbit-Antithymocyte Immunoglobulin Based Immunosuppressive Therapy Combined With Eltrombopag
by: Ruixin Li, et al.
Published: (2022-05-01)

TRANSFORMATION OF FOLLICULAR LYMPHOMA TO A BURKITT LYMPHOMA ASSOCIATED WITH HIV INFECTION AND PULMONARY TUBERCULOSIS
by: SLBG Oliveira, et al.
Published: (2023-10-01)

Safety and efficacy of eltrombopag in patients with aplastic anemia: a systematic review and meta-analysis of randomized controlled trials
by: Huaipeng Guo, et al.
Published: (2024-12-01)

Efficacy and safety of immunosuppressive therapy combined with eltrombopag for severe aplastic anemia: a systematic review and meta-analysis
by: Yan Zhang, et al.
Published: (2024-04-01)

Eltrombopag Preserves the Clonogenic Potential of Hematopoietic Stem Cells During Treatment With Antithymocyte Globulin in Patients With Aplastic Anemia
by: Margherita Vieri, et al.
Published: (2023-06-01)

S184: SAFETY AND OUTCOMES FOLLOWING IMMUNOSUPPRESSIVE THERAPY WITH ATG/CYCLOSPORIN +/- ELTROMBOPAG FOR OLDER PATIENTS WITH SEVERE APLASTIC ANEMIA
by: Ashvind Prabahran, et al.
Published: (2023-08-01)

Paroxysmal nocturnal hemoglobinuria‐phenotype cells predict a good response to eltrombopag in patients with refractory aplastic anemia
by: Ken Ishiyama, et al.
Published: (2020-07-01)

Comparison of eltrombopag and avatrombopag in the treatment of refractory/relapsed aplastic anemia: a single-center retrospective study in China
by: Zhuxin Zhang, et al.
Published: (2023-09-01)

Correlation of the Plasma Concentration of Eltrombopag With Efficacy in the Treatment of Refractory Aplastic Anemia: A Single-Centre Study in China
by: Wei Zuo, et al.
Published: (2020-11-01)

P766: ELTROMBOPAG EFFECTIVELY ALLEVIATES APLASTIC ANEMIA THROUGH REDUCING AKT PROTEIN STABILITY AND MODULATING T LYMPHOCYTE SUBSETS
by: Zenghua Lin, et al.
Published: (2023-08-01)

PB2041: COMPARISON OF ELTROMBOPAG AND AVATROMBOPAG IN THE TREATMENT OF REFRACTORY/RELAPSED APLASTIC ANEMIA, A SINGLE CENTER STUDY IN CHINA
by: Zhuxin Zhang, et al.
Published: (2023-08-01)

PB2069: ELTROMBOPAG WITH IMMUNO SUPPRESSIVE THERAPY IN SEVERE ACQUIRED APLASTIC ANEMIA IN CHILDREN AND ADOLESCENTS: A MONOCENTRIC EXPERIENCE
by: Nesrine Ben Sayed, et al.
Published: (2023-08-01)